XML 14 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Comprehensive Income - AUD ($)
 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2021
Revenue      
License revenue $ 0 $ 170,369 $ 0
Other income      
Research material sales 191,721 84,018 312,841
Grant income 3,314,001 4,459,974 3,549,965
Net gain on foreign exchange 623,511 1,228,122 0
Net gain on fair value movement of warrants 131,896 591,070 0
Interest income 938,999 224,520 105,327
Total revenue and other income 5,200,128 6,758,073 3,968,133
Expenses      
Research & development and intellectual property expenses (36,257,187) (31,341,576) (17,236,780)
Corporate administrative expenses (8,679,840) (7,210,123) (6,282,105)
Net loss on fair value movement of warrants 0 0 (8,663,013)
Net loss on foreign exchange 0 0 (507,042)
Finance costs (20,401) (92,430) (9,825)
Net Changes in fair value of convertible note liability (139,048) (324,736) (1,171,959)
Loss before income tax expense (39,896,348) (32,210,792) (29,902,591)
Income tax (expense)/ benefit 0 (34) [1] (33) [1]
Loss after income tax expense for the year (39,896,348) (32,210,826) (29,902,624)
Other Comprehensive Income/(Loss)      
Exchange differences on the translation of foreign operations 3,592,502 (922,327) (580,408)
Other comprehensive income/(loss) for the year, net of tax 3,592,502 (922,327) (580,408)
Total comprehensive income/(loss) for the year (36,303,846) (33,133,153) (30,483,032)
Loss for the year is attributable to:      
Owners of Immutep Limited (39,896,348) (32,210,826) (29,902,624)
Total comprehensive loss for the year is attributable to:      
Owners of Immutep Limited $ (36,303,846) $ (33,133,153) $ (30,483,032)
Basic loss per share $ (0.0447) $ (0.0379) $ (0.0503)
Diluted loss per share $ (0.0447) $ (0.0379) $ (0.0503)
[1] Income tax expense relates to tax payable for the Immutep subsidiary in the United States.